may 1st

Prime Editing: A Versatile Engineered CRISPR System

  • Targeting Efficiency and Flexibility: Observations of the enzyme's flexibility are drawn from targeting efficiency. Specifically, the site A7A7 is targeted with the highest efficiency, and the site A9A9 is targeted with identical efficiency. This indicates a high level of flexibility within the enzyme system.

  • Prime Editing (PE) Construction: Prime editing is characterized as an engineered version of the Cas9Cas9 protein. Unlike standard CRISPR systems, it can mutate bases (similar to base editors) but also possesses the ability to make specific insertions or deletions at target sites.

  • The Two-Component System: Prime editing utilizes a complex two-component system:   - Modified Cas9 Enzyme: This version of Cas9Cas9 is fused to a reverse transcriptase (RT) and other potential modular attachments.   - Prime Editing Guide RNA (pegRNA): The pegRNApegRNA is more complex than a standard sgRNAsgRNA. It contains sequences for target recognition and an additional sequence at the 3′3' end that serves as a template for the reverse transcriptase.

Scope and Therapeutic Impact of Prime Editing

  • Mutational Capability: The prime editor can perform:   - All transition mutations (described in the transcript as purine to purine or purine to purine transitions).   - All eight transversion point mutations (described as purine to purine or purine to purine transversions).   - Sophisticated single-step engineering of insertions and deletions.

  • Impact on Human Genetic Disorders: Research into pathogenic human mutations indicates:   - Approximately 50%50\% (exactly half) of known genetic disorders are point mutations (transitions or transversions), all of which are treatable via prime editing.   - Including insertions and deletions, approximately two-thirds (23\frac{2}{3}) of known human genetic mutations can be addressed.   - Quantitative Scale: Out of the approximately 75,00075,000 known genetic disorders, roughly 50,00050,000 are directly treatable using prime editing methods.

The Prime Editing Mechanism and Optimization

  • Step-by-Step Mechanism:   - Recognition: The Cas9Cas9 nickase, fused to reverse transcriptase, recognizes the target via the pegRNApegRNA. Identifying the target requires a Protospacer Adjacent Motif (PAMPAM).   - Nicking: The enzyme creates a nick on the non-recognized DNA strand.   - Extension: The reverse transcriptase uses the 3′3' end generated by the nick to extend the DNA, using the RNA template provided by the pegRNApegRNA. The intended edit (e.g., a three-base change) is incorporated during this synthesis.   - Resolution: Once the prime editor dissociates, a "flap" of DNA remains. The cell's repair machinery must resolve this mismatch by chipping away at the old DNA flap and replacing it with the newly synthesized, edited sequence.

  • System Evolution: Since the initial description in 20192019, the system has been optimized through numerous permutations to improve functionality. A review published three years after the initial report (20222022) highlights variants designed for:   - Improved nuclear and cellular localization.   - Enhanced expression and DNADNA nicking.   - Better chromatin accessibility.   - High activity in plants (where prime editing is used extensively).

Engineering the pegRNA and Enzyme Components

  • RNA Polymerase III (Pol III): Evolution of the system involves using PolIIIPol III for pegRNApegRNA expression rather than PolIIPol II. In eukaryotes, PolIIIPol III synthesizes non-messenger RNAs like tRNAstRNAs and small nuclear RNAs (snRNAssnRNAs). It is highly effective at producing small RNA fragments that are not intended for translation.

  • pegRNA Protection: Three evolved versions of the pegRNApegRNA have been developed to resist degradation by ribonucleases. These include modifications such as the AG quad complex to stabilize the small RNA molecules.

  • Clinical Timeline: Prime editing was described only seven years ago (relative to the lecture timeline) and is already entering clinical applications.

Managing Off-Target Effects and Protein Size

  • Off-Target Activity: Cas9Cas9 does not always bind exclusively to its programmed target. There is a trade-off between binding strength and specificity. While high binding strength ensures activity, it also increases off-target effects.

  • Binding Affinity Engineering: To reduce off-target binding, researchers have mutated specific basic residues in the Cas9Cas9 protein, such as Arginine (RR) and Lysine (KK). By removing these positive charges, the enzyme's interaction with the negatively charged DNADNA backbone is loosened, which effectively reduces off-target binding while maintaining sufficient catalytic activity for the intended site.

  • Protein Size Constraints:   - Standard Cas9Cas9 is a massive protein, weighing approximately 500 kilodaltons500\,\text{kilodaltons}.   - Gene Therapy Vectors: Adeno-associated virus (AAVAAV) vectors have a strict cargo limit of approximately 4,000 bases4,000\,\text{bases}.   - Smaller versions of Cas9Cas9 have been described for over ten years to address this limitation.   - The "Operating System" Metaphor: Scientists are often hesitant to switch from the original Cas9Cas9 to smaller variants because the original system has a massive established "tool set." Switching to a new protein is likened to moving to a new computer operating system that lacks the mature software and tools of the established one.

Delivery Mechanisms for CRISPR-Cas9

  • In Vitro Culture: Cells like stem cells or bone marrow can be grown in culture and transformed with a plasmid expressing the guide RNA and Cas9Cas9. This carries a risk of permanent alteration if the cell continues to produce these components.

  • Ribonucleoprotein (RNP) Injection: For a one-time edit, the preassembled protein and RNA can be injected directly. This works once and then degrades, leaving the cell modified but without permanent expression of editing tools.

  • mRNA Injection: Messenger RNA can be injected to be translated into protein within the cell.

  • Dual Delivery Strategy: A combined approach might use an AAVAAV to deliver the guide RNA and repair template alongside other delivery methods for the enzyme components.

Questions & Discussion

  • Question: Why would you want to use PolIIIPol III rather than PolIIPol II?

  • Answer: RNARNA polymerase III is responsible for synthesizing non-messenger RNA, such as tRNAstRNAs and small nuclear RNAs. It is better at making short, functional pieces of RNA that are not intended for translation, making it ideal for guide RNA production.

  • Question: Does reducing a binding site strength alter Cas9's ability to carry out its function at all?

  • Answer: Yes, there is likely a trade-off. By lowering affinity for DNADNA, you may reduce overall activity, but as long as the catalytic activity remains functional at the target site, the trade-off is often acceptable to gain higher specificity.

  • Question: Can smaller versions of Cas9Cas9 recognize the same length of targets as the standard Cas9Cas9?

  • Answer: Generally, they recognize similar lengths, approximately 2020 bases. While it depends on the specific enzyme, the specificity length of around 2020 bases is standard across these systems.

  • Note on Logistics: A quiz is scheduled for Wednesday covering material up through CRISPR. A study guide will be posted. The quiz format offers "15 chances to get 10 points."